{"id":102909,"date":"2024-11-08T09:12:00","date_gmt":"2024-11-08T12:12:00","guid":{"rendered":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/bright-peak-therapeutics-presents-new-data-at-the-2024-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc\/"},"modified":"2024-11-08T09:12:00","modified_gmt":"2024-11-08T12:12:00","slug":"bright-peak-therapeutics-presents-new-data-at-the-2024-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc","status":"publish","type":"post","link":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/bright-peak-therapeutics-presents-new-data-at-the-2024-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc\/","title":{"rendered":"Bright Peak Therapeutics Presents New Data at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)"},"content":{"rendered":"

Bright Peak Therapeutics, Inc.<\/b><\/p>\n

— BPT958, a bifunctional PD-1 immunoconjugate with a masked IL-2 payload designed to be processed specifically in the tumor microenvironment –<\/em><\/p>\n

–In preclinical models, BPT958 induces potent antitumor activity with minimal systemic activation –<\/em><\/p>\n

BASEL, Switzerland and SAN DIEGO, Nov. 08, 2024 (GLOBE NEWSWIRE) — Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the presentation of BPT958, a new investigational cancer immunotherapy agent at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held on November 8-10, 2024, in Houston, TX.<\/p>\n

BPT958 is designed to combine two key immuno-stimulatory mechanisms of action into a single molecule, including coordinated PD-1\/PD-L1 checkpoint blockade in tandem with a tumor-targeted delivery of IL-2 to T cells within the tumor microenvironment (TME). Preclinical studies demonstrate that BPT958 induces potent, synergistic anti-tumor immune responses superior to PD-1 blockade alone, with activity in both PD-1-sensitive and PD-1-resistant tumor models.<\/p>\n

Here we introduce BPT958, a bifunctional PD1-IL2 immunoconjugate with an optimized and masked IL-2 payload, said Dr. Jon Wigginton, President of Research and Development at Bright Peak. “We rationally designed our tumor-activated IL-2 payload with the intent of selectively targeting antigen-experienced PD-1+<\/sup> Teff<\/sub> cells in the tumor microenvironment. We believe that this approach ultimately could yield a more favorable safety profile and increased therapeutic window compared to non-masked IL-2 approaches, and leverage the potential for use of BPT958 alone or in combination with other therapeutics for patients with a range of cancers.”<\/p>\n

Details regarding the upcoming SITC abstract presentations are as follows:<\/strong><\/p>\n

November 9, 2024, 9:00 AM 9:00 PM (EST)<\/strong>
Poster 1320: Identification of PD1-IL2<\/strong>TAP<\/strong><\/sub> a PD-1 Blocking Immunoconjugate Harboring a Tumor-Activatable Masked IL-2 Payload Lacking Binding to IL2R<\/strong>\/CD122 <\/strong><\/p>\n

Abstract Highlights <\/strong><\/p>\n